Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Tardif, J.-C.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Tardif, J.-C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2005. All rights reserved. For Permissions, please e-mail: permissions@oupjournals.org

Ivabradine in clinical practice: benefits of If inhibition

Jean-Claude Tardif*

Montreal Heart Institute, 5000 Belanger Street, Montreal, Quebec H1T 1C8, Canada

* Corresponding author. Tel: +1 514 376 3330 ext. 3564; fax: +1 514 593 2500. E-mail address: jean-claude.tardif{at}icm-mhi.org

Relieving the symptoms of angina and improving the quality of life and functional status are important objectives in the management of patients with chronic stable angina. A high heart rate induces or exacerbates myocardial ischaemia and angina, because it both increases oxygen demand and decreases myocardial perfusion, the latter by shortening the duration of diastole. Moreover, there is a large body of evidence about the relationship between high resting heart rate and mortality, documented in different population types. ß-Blockers are effective in reducing angina largely by decreasing heart rate. Physician use and patient compliance may be limited by the side effects of ß-blockers, which include fatigue, depression, and sexual dysfunction. Heart rate reduction can also be obtained by some calcium antagonists and by the new agent ivabradine. Ivabradine (Procoralan) is a selective and specific If inhibitor, which acts on one of the most important ionic currents for the regulation of the pacemaker activity of sinoatrial node cells. Ivabradine has demonstrated dose-dependent anti-ischaemic and anti-anginal effects at dosages of 5, 7.5, and 10 mg bid in an extensive programme of more than 5000 patients. The non-inferiority of ivabradine was shown vs. the ß-blocker atenolol and the calcium-channel blocker amlodipine. Unlike ß-blockers, ivabradine is devoid of intrinsic negative inotropic effects and does not affect coronary vasomotion. A whole range of patients with angina may benefit from exclusive heart rate reduction with ivabradine, including those with contraindications or intolerance to the use of ß-blockers and patients who are insufficiently controlled by ß-blockers or calcium-channel blockers.

Key Words: Angina • Heart rate • Pharmacology


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Eur Heart J SupplHome page
M. Tendera
Editorial: If inhibition: from pure heart reduction to treatment of stable angina
Eur. Heart J. Suppl., September 1, 2005; 7(suppl_H): H3 - H6.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.